Journal Article Describes New Strategies to Categorize Blood for Proteomic Biomarker Discovery
MONMOUTH JUNCTION, NJ, April 23, 2020 – A journal article by Biotech Support Group, with co-authors from Vanderbilt University Medical Center and Rutgers Proteomics Center, describes new strategies for proteomic investigation of blood components.

News Release

Journal Article Describes New Strategies to Categorize Blood for Proteomic Biomarker Discovery


MONMOUTH JUNCTION, NJ, April 23, 2020 – A journal article by Biotech Support Group, with co-authors from Vanderbilt University Medical Center and Rutgers Proteomics Center, describes new strategies for proteomic investigation of blood components.



Citation is:

Kuruc M, Zheng H, Sowerhardy A, Avadhani S, Roy D, et al. (2020) New Strategies to Categorize Blood for Proteomic Biomarker Discovery. Proteomics & Bioinformatics, 2(2): 90-107.


Although much effort has gone into genomic sequencing to define disease, the downstream products of gene sequences-proteins, nevertheless remain the master regulators of biology. Many proteins are measurable in blood, making it a rich resource for biomarkers. Yet for reasons largely unrelated to analytical limitations, this resource remains largely untapped. In this review, we describe how chronic illness manifests itself in blood and how we might study innate immunity to understand mechanisms that can potentially translate into new biomarkers and therapeutic modalities.


We draw upon BSG's knowledgebase of proteome information reportable after using depletion or enrichment products in LC-MS/MS workflows and how this knowledge can be utilized in new strategies for biomarker discovery from blood samples. We note that BSG’s products have simply and efficiently reduced the complexity of the serum proteome allowing for cost-effective workflows, without the use of antibody-based depletion methods. Finally, we discuss how patterns of Serpins, a superfamily of protease inhibitors, may serve as a surrogate measure of the progressive stages of the innate immune systems’ response to both infectious and noninfectious disease. This convergence of strategies and LC-MS/MS technologies has made the task immediately available to investigators to now develop the next generation of molecular tests for more precise and personalized treatment of patients.


Swapan Roy, Ph.D., President and Founder of Biotech Support Group, concurs stating “Proteomics started with annotation and Venn diagrams but now the field demands robust quantitation. This has been our focus; how to address quantitative differences between proteins in blood samples representing a challenge or disease state, vs. samples representing a normal or control state. Ultimately, biomarkers derived from blood provides the most useful clinically actionable biomarkers so that is why our product line is focused on all blood compartments, both cellular and extracellular. We argue in this report for characterization of the innate immune response, as proteins derived from it imparts a wide range of effects in infectious and non-infectious disease. The innate response proteome also is in the sweet spot of LC-MS analysis. Furthermore, an over-exuberant innate immune response is now one of the challenges the world faces with COVID-19 induced acute respiratory distress syndrome (ARDS). We hope with the strategies described in this report, we can find and develop biomarkers to not only better characterize disease but provide a better understanding of how the innate immune response becomes dysregulated in chronic disease, with consequences for acute disease. From this, we hope to gain further insight so that healthcare professionals can develop new and sometimes repurpose approved therapies, to address many diseases; COVID-19 being one of many with a highly engaged inflammatory component.


For more information on the BSG complete line of Albumin & IgG Removal products, visit: https://www.biotechsupportgroup.com/Articles.asp?ID=451


About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group (BSG) develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients.


For more information, go to http://www.biotechsupportgroup.com. For business development, contact Matt Kuruc at mkuruc@biotechsupportgroup.com